Product Description
Mechanisms of Action: DNA Gyrase Inhibitor,TOP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Egypt | Japan | Korea
Approved Indications: None
Known Adverse Events: None
Company: FUJIFILM Toyama Chemical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pneumonia, Mycoplasma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-132273 | P3 |
Completed |
Pneumonia, Mycoplasma |
None |